Mylan's EpiPen Settlement on Defrauding Medicaid Gets Finalized

Bloomberg ------- Mylan NV’s $465 million settlement of a U.S. case that claimed the drugmaker defrauded taxpayers by misclassifying its allergy-shot EpiPen product as a generic drug was finalized by the Justice Department.The settlement, announced by the Justice Department on Thursday, resolves claims that Mylan misclassified EpiPen to avoid paying rebates owed to the government. The drugmaker disclosed an agreement last year, but government officials wouldn’t confirm it until now. The deal had sparked criticism from some U.S. lawmakers who said it wasn’t tough enough on the company. To learn more click on the picture below to read the article.